Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- The phase III DRIVE-AHEAD trial compared doravirine with efavirenz in treatment-naive adults[Orkin 2019]
- Doravirine was found to be noninferior to efavirenz, with consistent virologic suppression rates (HIV-1 RNA < 50 copies/mL) across most patient subgroups with the exception of those defined by age
Based on results of DRIVE-AHEAD and the phase III DRIVE-FORWARD trial, the FDA approved doravirine for treatment-naive adults, both as a single agent to be used in combination with other ARVs and as a once-daily, single-tablet regimen coformulated with lamivudine and tenofovir DF[FDA Doravirine; FDA DOR/3TC/TDF]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content